MESNEX Drug Patent Profile

When do Mesnex patents expire, and when can generic versions of Mesnex launch?

Mesnex is a drug marketed by Baxter Hlthcare and is included in two NDAs.

The generic ingredient in MESNEX is mesna. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the mesna profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mesnex

A generic version of MESNEX was approved as mesna by FRESENIUS KABI USA on April 26^th, 2001.

Summary for MESNEX

US Patents:	0
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for MESNEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	MESNEX	mesna	INJECTABLE;INTRAVENOUS	019884-001	Dec 30, 1988	AP	RX	Yes	Yes
Baxter Hlthcare	MESNEX	mesna	TABLET;ORAL	020855-001	Mar 21, 2002	AB	RX	Yes	Yes

International Patents for MESNEX

See the table below for patents covering MESNEX around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	217123	Eljárás javított stabilitású Mesna injekciós oldatok előállítására (PROCESS FOR PRODUCTION OF MESNA INJECTION SOLUTIONS WITH IMPROVED STABILITY)
Finland	111804
Germany	4233842
Japan	3636372
Bulgaria	60851
Ireland	782404

Last updated: February 3, 2026

What is MESNEX?

MESNEX (mesna) is a chemoprotective agent used to prevent hemorrhagic cystitis caused by alkylating agents like cyclophosphamide and ifosfamide. It is administered intravenously and occasionally orally in clinical settings. MESNEX's primary role is to detoxify reactive metabolites of chemotherapy drugs, reducing bladder toxicity.

What is the Current Market Landscape for MESNEX?

The global market for mesna, including MESNEX, is expected to grow due to increased adoption in oncology protocols. Major regions include North America, Europe, and Asia-Pacific, with the U.S. leading due to high cancer treatment rates and robust healthcare infrastructure.

Market Size and Growth

Metric	2022	Projected 2027	CAGR (2022-2027)
Global mesna market value	~$120 million	~$180 million	8.2%
North America	~$60 million	~$90 million	8.1%
Europe	~$30 million	~$45 million	8.2%
Asia-Pacific	~$20 million	~$30 million	8.3%

The growth is driven by the rising incidence of cancers requiring alkylating chemotherapy, with an emphasis on supportive care.

How Does MESNEX Fit Within the Broader Oncology and Supportive Care Market?

It complements a broad portfolio of supportive agents like antiemetics, growth factors, and hydration solutions. The supportive care market for oncology treatments was valued at approximately $13 billion in 2022 and is expected to grow at a CAGR of around 6% through 2027. Mesna's role remains niche but critical for specific chemotherapy regimens.

What Are the Key Fundamentals for Investment in MESNEX?

1. Market Penetration and Growth Drivers

• Increasing prevalence of cancers (e.g., lymphoma, breast, ovarian) annually increases the demand for MESNEX.
• Adoption of MESNEX in clinical protocols by hospitals and cancer centers.
• Rising awareness among healthcare providers regarding the drug's protective benefits.

2. Competitive Landscape

• MESNEX is primarily supplied by a limited number of pharmaceutical companies, including Merck KGaA and others in generics.
• Entry barriers exist due to manufacturing complexity and regulatory requirements.
• Few direct competitors, but multiple generic versions can pressure pricing.

3. Regulatory and Reimbursement Environment

• Regulatory approval agencies like the FDA, EMA, and other health authorities have approved MESNEX.
• Reimbursement policies in major markets incentivize use in standard chemotherapy protocols.
• Potential risks from regulatory changes or patent expirations.

4. R&D and Pipeline Considerations

• No substantial pipeline for MESNEX as a single-agent product.
• Research ongoing into alternative chemoprotectants or combination therapies, but MESNEX maintains niche status.

5. Manufacturing and Supply Chain Factors

• MESNEX's synthesis involves specialized processes with quality and safety standards.
• Supply chain resilience is crucial amid global disruptions.

What Are the Key Investment Risks?

• Patent expirations in key markets could lead to increased generic competition and price erosion.
• Market saturation in mature regions may limit growth.
• Regulatory risks include potential safety concerns, although no major issues currently.
• Emerging alternatives or novel chemoprotectants could displace MESNEX.

What Is the Future Outlook for MESNEX?

Growth is primarily dependent on cancer treatment trends, supportive care guidelines, and geographical expansion. The outlook is moderate; with solid demand in established markets, high-growth potential exists in emerging regions. Innovation in supportive care could influence its market share.

What Are the Financial and Strategic Implications?

• Revenue streams are relatively stable owing to established clinical use.
• Profitability can improve with scale and cost efficiencies.
• companies with robust manufacturing capabilities and established sales channels have an advantage.

Key Takeaways

• MESNEX is a niche, high-value supportive agent in chemotherapy.
• Market growth aligns with rising cancer incidence; growth rate around 8% CAGR.
• Limited competitors, primarily generics, dominate the landscape.
• Risks include patent expiry, regulatory developments, and competitive dynamics.
• Future growth hinges on global oncology treatment trends and supportive care adoption.

FAQs

1. What is the primary clinical use of MESNEX?
It prevents hemorrhagic cystitis caused by alkylating chemotherapy agents.

2. Who are the main suppliers of MESNEX?
Major suppliers include Merck KGaA and other generic manufacturers.

3. How does MESNEX generate revenue?
Through hospital and oncology clinic prescriptions worldwide, especially in mature markets.

4. What factors could threaten MESNEX's market position?
Patent expirations, generic competition, and alternative chemoprotectants.

5. What is the outlook for MESNEX in emerging markets?
Expanding use due to increasing cancer treatment infrastructure, with growth potential exceeding developed regions.

References

[1] MarketsandMarkets. Chemoprotective agents market report, 2022.
[2] IQVIA. Oncology supportive care market analysis, 2022.
[3] Statista. Cancer treatment statistics, 2022.
[4] U.S. FDA. MESNEX approval and safety information.